Medicaid's Bold Move: Paying for Cures, Not Just Drugs

A new federal payment model allows Medicaid to cover costly gene therapies for sickle cell disease, offering a potential cure for affected patients. This initiative sees the government negotiating prices with manufacturers and ensuring accountability for treatment outcomes.

The federal government negotiates discounts and rebates from drugmakers if treatments prove unsuccessful. This contrasts with traditional payment models where bills are settled regardless of patient benefit. The gene therapies, approved in late 2023 for individuals aged 12 and older, come with a price tag of $2.2 million to $3.1 million per patient, excluding hospitalization costs.

This payment strategy, initiated under the Biden administration and continued by the Trump administration, aims to tackle high drug costs. By December 2024, 33 states, Washington D.C., and Puerto Rico had joined the program. The initiative could pave the way for similar payment arrangements for other expensive therapies, particularly for rare diseases.

Serenity Cole, an 18-year-old who underwent gene therapy in May, experienced significant relief from sickle cell disease, a condition that previously caused daily pain and frequent hospitalizations. Her successful treatment highlights the potential of this therapy and the new payment model facilitating access.